Biotech Values

[DewDiligence]

OCUL—…there were clearly a large number of more minor safety issues compared to eylea. Probably mostly related to having a high dose of a TKI (much broader activity than VEGF mab), so potentially getting worse on redosing…

Moreover, absent a vitretomy, the TKI elution cannot be stopped if there’s a more serious safety problem.

Based on currently available information this is not a treatment I would want for myself or a family member. Regrettably, I do have a family history of wet AMD.